TY  - JOUR
AU  - Sarmiento-Maldonado, Mauricio
AU  - Ramirez-Villanueva, Pablo
AU  - Cortes-Monroy, Pablo Bertin 
AU  - Jara-Arias, Veronica
AU  - Soto-Donoso, Katherine
AU  - Uribe-Gonzalez, Pablo
AU  - Ocqueteau-Tachini, Mauricio
AU  - Perez-Simon, Jose Antonio
PY  - 2017
DO  - 10.1186/s40164-017-0092-3
SN  - 2162-3619
UR  - https://hdl.handle.net/10668/27873
T2  - Experimental hematology & oncology
AB  - Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown...
LA  - en
KW  - Corticoid refractoriness
KW  - Extracorporeal photopheresis
KW  - Graft versus host disease
KW  - Ruxolitinib
KW  - Primary Myelofibrosis
KW  - Photopheresis
KW  - Graft vs Host Disease
KW  - Bronchiolitis Obliterans Syndrome
KW  - Steroids
TI  - Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.
TY  - research article
VL  - 6
ER  -